Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 5/20/2018 |
| Start Date: | November 2005 |
| End Date: | December 2020 |
| Contact: | Marzieh Salehi, MD MS |
| Email: | salehi@uthscsa.edu |
| Phone: | 210-567-6691 |
The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery
The overall goal of this project is to understand the mechanisms by which gastric bypass
surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit
with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins
that improve insulin secretion and glucose metabolism. The study is divided into three
specific aims.
1. To determine the role of incretin hormones on insulin secretion in patients with gastric
bypass surgery using intravenous-oral hyperglycemic clamp.
2. To compare incretin effect and glucose tolerance among patient who suffer from
hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit
with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins
that improve insulin secretion and glucose metabolism. The study is divided into three
specific aims.
1. To determine the role of incretin hormones on insulin secretion in patients with gastric
bypass surgery using intravenous-oral hyperglycemic clamp.
2. To compare incretin effect and glucose tolerance among patient who suffer from
hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
The overall goal of this project is to understand the mechanisms by which gastric bypass
surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit
with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins
that improve insulin secretion and glucose metabolism. The study is divided into three
specific aims.
1. To determine the role of incretin hormones on insulin secretion in patients with gastric
bypass surgery using intravenous-oral hyperglycemic clamp.
2. To compare incretin effect and glucose tolerance among patient who suffer from
hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit
with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins
that improve insulin secretion and glucose metabolism. The study is divided into three
specific aims.
1. To determine the role of incretin hormones on insulin secretion in patients with gastric
bypass surgery using intravenous-oral hyperglycemic clamp.
2. To compare incretin effect and glucose tolerance among patient who suffer from
hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals.
3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Inclusion Criteria:
- age 18-65
- healthy control without diabetes or active organ disease
- Individuals with bariatric surgery
- recurrent hypoglycemia post gastric bypass
Exclusion Criteria:
- pregnancy
- significant anemia
- diabetes currently unless pre-op for bariatric surgery procedure
- GI obstruction
We found this trial at
1
site
San Antonio, Texas 78229
Principal Investigator: Marzieh Salehi, MD
Phone: 210-567-6691
Click here to add this to my saved trials
